TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8836663
Drug: MR889, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR889, 500 mg b.i.d. for 4 weeks
Study: 8836663
Drug: MR889, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR889, 500 mg b.i.d. for 4 weeks (subset with short disease duration)
Study: 27472565
Drug: CCDS-administered IL
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCDS-administered IL anesthesia
Study: 25410083
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (manipulation) with supervised exercise regime
Study: 19878101
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of 20% albumin
Study: 19878101
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of Ringer's acetate solution
Study: 12564609
Drug: Sibenadet (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibenadet (500 microg three times daily) plus placebo (twice daily)
Study: 12564609
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 microg twice daily) plus placebo (three times daily)
Study: 12564609
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily) plus a second placebo (three times daily)
Study: 8628600
Drug: Phenobarbital (PB)
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (PB) therapy, 10 mg/kg IV followed by 100 mg orally daily until delivery.
Study: 25196976
Drug: Ceftolozane/tazobactam (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftolozane/tazobactam (doses ranging from 500 to 3000 mg)
Study: 21173169
Drug: Alcohol consumption
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol consumption (per 10 g ethanol/d)
Study: 11124286
Drug: Low-dose 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose 5-fluorouracil (3 subconjunctival injections of 5 mg each over 11 postoperative days)
Study: 1364168
Drug: All antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: All antihistamines
Study: 3974097
Drug: Oral albuterol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral albuterol, 4 mg
Study: 3974097
Drug: Oral metaproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metaproterenol sulfate, 20 mg
Study: 3974097
Drug: Oral terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline sulfate, 5 mg
Study: 26406192
Drug: Tetrax group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrax group (TG) - 15 minutes exercise session 3 times weekly for 4 weeks
Study: 26406192
Drug: Electrostimulation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrostimulation group (EG) - 40 minutes electrostimulation of postural muscles 3 times weekly for 4 weeks
Study: 26420180
Drug: 1000 μg
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 μg of vitamin B‐12
Study: 26420180
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g fish oil
Study: 26420180
Drug: 1000 μg
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 μg vitamin B‐12 and 2 g fish oil
Study: 21906811
Drug: TB-403 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB-403 (0.3 to 5.0 mg/kg)
Study: 18362604
Drug: Lidocaine‐prilocaine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine‐prilocaine cream (positive control)
Study: 12356389
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg/day) + L-arginine
Study: 7867175
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin patches applied for 12 hours daily for 30 days
Study: 7867175
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin therapy
Study: 1959368
Drug: sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate (1 g every 6 hrs)
Study: 1959368
Drug: ranitidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine (50 mg every 6 hrs)
Study: 7124567
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of vitamin B6 and magnesium
Study: 28356136
Drug: Slow continuous
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow continuous infusion with hypertonic saline
Study: 27108405
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg subcutaneous injections, 6 doses total, starting on day one and every 6 months until 30 months)
Study: 27108405
Drug: Placebo (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous injections, 6 doses total, starting on day one and every 6 months until 30 months)
Study: 24074637
Drug: Sodium benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium benzoate (250-750 mg/day)
Study: 9935129
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing of progestin (5 mg twice per week)
Study: 9935129
Drug: Continuous dosing
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous dosing of progestin (2.5 mg daily)
Study: 9935129
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (intermittent and continuous dosing)
Study: 2149829
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 1:200,000 epinephrine (Group L)
Study: 2149829
Drug: 60 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 micrograms sufentanil without test dose (Group S‐)
Study: 6987026
Drug: Fluproquazone (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluproquazone (75 to 200 mg)
Study: 6987026
Drug: Fluproquazone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluproquazone (100 to 150 mg)
Study: 31707286
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg of vitamin D supplementation
Study: 31707286
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg of vitamin D supplementation
Study: 31707286
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 μg of vitamin D)
Study: 31707286
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg and 25 μg of vitamin D supplementation
Study: 8971536
Drug: 5‐fluorouracil 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil 5% (5‐FU) topical application plus Interferon alpha‐2a (IFA alpha‐2a) (high dose)
Study: 8971536
Drug: CO2 laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 laser vaporization plus 5‐FU plus Interferon alpha‐2a (IFA alpha‐2a) (high dose)
Study: 6365156
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day of danazol
Study: 28295907
Drug: Omission of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omission of HF medication for 48 hours
Study: 28295907
Drug: Regular medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular medication
Study: 25764513
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of oral cholera vaccine at 14 day interval
Study: 25764513
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of oral cholera vaccine at 28 day interval
Study: 23724913
Drug: Chemotherapy (pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (pemetrexed 500 mg/m² or docetaxel 75 mg/m² every 3 weeks)
Study: 20578380
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (analgesic)
Study: 14762984
Drug: Complementary medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary medicine intervention (specifics not provided)
Study: 14762984
Drug: Physician MD
Normalized name: miconazole nitrate Topical Solution [Nail MD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician MD as complementary medicine practitioner
Study: 14762984
Drug: Teaching complementary
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teaching complementary medicine in medical and nursing schools
Study: 14762984
Drug: Knowledge about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge about adverse reactions to complementary therapies
Study: 14762984
Drug: Legalizing complementary
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Legalizing complementary medicine
Study: 11000645
Drug: Paroxetine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (n = 137), starting at 10 mg/d and titrated to a maximum of 40 mg/d
Study: 11000645
Drug: Problem-solving treatment-primary
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving treatment-primary care (PST-PC; n = 138)
Study: 8792922
Drug: Mizolastine 10
Normalized name: mizolastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine 10 mg once daily (n = 29)
Study: 27068252
Drug: Cellphone Assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellphone Assisted Remote Observation of Medication Adherence (CAROMA)
Study: 27068252
Drug: Active study
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active study medication
Study: 15942151
Drug: Local estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local estrogen cream
Study: 20102444
Drug: Local estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local estrogen and testosterone cream
Study: 20102444
Drug: Nonhormonal lubricant
Normalized name: Eyes Alive Lubricating
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonhormonal lubricant KY gel (control)
Study: 17914966
Drug: Lactoferrin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin monotherapy for 8 weeks followed by lactoferrin, interferon, and ribavirin for 24 weeks
Study: 17914966
Drug: Lactoferrin, interferon,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin, interferon, and ribavirin combination therapy
Study: 8853250
Drug: Chronic gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic gastric distension (500 ml balloon)
Study: 27149465
Drug: Radial Extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial Extracorporeal Shock Wave Therapy (rESWT) - 1 session per week for 3 weeks
Study: 27149465
Drug: Radial Extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial Extracorporeal Shock Wave Therapy (rESWT) - 1 single session
Study: 27149465
Drug: Radial Extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial Extracorporeal Shock Wave Therapy (rESWT) - 3 sessions
Study: 18474343
Drug: Low-dose carvedilol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose carvedilol coupled with nurse management
Study: 7751427
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation of sustained-release verapamil in fed subjects
Study: 7751427
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of sustained-release verapamil in fed subjects
Study: 7751427
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation of sustained-release verapamil in fed subjects (rapid absorbers)
Study: 2089973
Drug: Oral Amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Amphotericin B (2 g/day)
Study: 7443592
Drug: Heparin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin with Intralipid
Study: 7443592
Drug: Control (Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Heparin without Intralipid)
Study: 30324839
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration salts plus health education
Study: 23384404
Drug: Vancomycin 125
Normalized name: vancomycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 125 mg four times/day
Study: 23384404
Drug: Vancomycin 250
Normalized name: vancomycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 250 mg four times/day
Study: 23384404
Drug: Metronidazole 250
Normalized name: metronidazole 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 250 mg three times/day
Study: 23384404
Drug: Metronidazole 500
Normalized name: metronidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg three times/day
Study: 23384404
Drug: Metronidazole (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (any dose)
Study: 21097838
Drug: Packed RBC
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Packed RBC transfusion (15 ml/kg) at high ('liberal') haematocrit thresholds
Study: 21097838
Drug: Packed RBC
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Packed RBC transfusion (15 ml/kg) at low ('restrictive') haematocrit thresholds
Study: 16925686
Drug: Probiotics (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (combination of four probiotic strains)
Study: 11328901
Drug: Alternative antihypertensive
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative antihypertensive therapy (Control)
Study: 8026202
Drug: Closer injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closer injection port to the introducer sheath and more open introducer sheath sidearm
Study: 8026202
Drug: Cold saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold saline injection port of the pulmonary artery catheter downstream of the introducer sheath and closed introducer sidearm
Study: 2690999
Drug: Minaprine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minaprine (100 mg t.d.s. and 100 mg b.d.)
Study: 2690999
Drug: Mianserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (20 mg t.d.s.)
Study: 962291
Drug: Continuous oestriol
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oestriol succinate therapy (2 mg/day) for three years
Study: 962291
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without hormone therapy
Study: 31473331
Drug: Spanish-language self-help
Normalized name: Spanish thyme oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spanish-language self-help smoking cessation intervention (10 booklets, 9 pamphlets, and a booklet for family and friends mailed monthly over 18 months)
Study: 25996892
Drug: Darbepoetin low
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin low dose (2 μg/kg)
Study: 25996892
Drug: Darbepoetin high
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin high dose (10 μg/kg)
Study: 21557814
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (intra-arterial thrombolysis with alteplase, possibly associated with mechanical clot disruption and/or retrieval)
Study: 21557814
Drug: Systemic intravenous
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic intravenous thrombolysis with alteplase
Study: 17563309
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin and oral agents
Study: 11440218
Drug: norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: norfloxacin 400 mg b.i.d. for 10 d
Study: 11440218
Drug: ceftibuten 200
Normalized name: ceftibuten 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftibuten 200 mg b.i.d. for 10 d
Study: 7800216
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg day 1 + 100 mg day 2)
Study: 21122176
Drug: Low-sodium physiologically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium physiologically based solution
Study: 18528671
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (SIT) for atopic dermatitis
Study: 18528671
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (SIT) for food allergies
Study: 17162712
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate + combined estradiol/norethisterone acetate therapy (GA/CENT)
Study: 15018017
Drug: Low-dose isotretinoin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose isotretinoin (0.15-0.40 mg/kg per day)
Study: 15018017
Drug: High-dose isotretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose isotretinoin (0.5-1.0 mg/kg per day)
Study: 7942583
Drug: Sodium alginate
Normalized name: Sodium Alginate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium alginate (7.5 g)
Study: 2452915
Drug: Two enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two enzyme preparations tested
Study: 2452915
Drug: Pancreatic enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic enzyme replacement therapy
Study: 29478819
Drug: Vestronidase alfa
Normalized name: Vestronidase alfa
DrugBank: Vestronidase alfa (DB12366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vestronidase alfa treatment for 24 weeks
Study: 28679554
Drug: Whey and
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey and calcium (whey+); 45-48 g/d
Study: 28679554
Drug: Whey; 45-48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey; 45-48 g/d
Study: 28679554
Drug: Soy; 45-48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy; 45-48 g/d
Study: 28679554
Drug: Maltodextrin (control);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin (control); 45-48 g/d
Study: 1389521
Drug: CMF x
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF x six (cyclophosphamide 100 mg/m2 orally on days 1‐14, methotrexate 40 mg/m2 intravenously on days 1 and 8, fluorouracil 600 mg/m2 intravenously on days 1 and 8 for six cycles)
Study: 29338584
Drug: betaHB salts
Approvals — FDA: no, EMA: no, PMDA: no
Description: betaHB salts (0.38 g kg body mass‐1) in plain water (3.8 mL kg body mass‐1)
Study: 29338584
Drug: plain water
Approvals — FDA: no, EMA: no, PMDA: no
Description: plain water (3.8 mL kg body mass‐1)
Study: 22551127
Drug: Radioiodine dose
Normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine dose of 1.1 GBq
Study: 22551127
Drug: Radioiodine dose
Normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine dose of 3.7 GBq
Study: 22551127
Drug: Thyrotropin-stimulation method
Normalized name: Thyrotropin
DrugBank: Thyrotropin (DB15263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-stimulation method using thyroid hormone withdrawal
Study: 22551127
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of radioiodine (1.1 GBq and 3.7 GBq)
Study: 21265192
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac Sodium Sustained Release Tablets
Study: 18206735
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g ethylic alcohol (149 ml of Gordon's Gin)
Study: 18206735
Drug: 149 ml
Normalized name: anakinra 149 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 149 ml of water (placebo)
Study: 8534699
Drug: Once-daily dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dose gentamicin (40 mg/2 L dialysate)
Study: 8534699
Drug: Multiple-dose gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose gentamicin (10 mg/2 L dialysate administered 4 times per day)
Study: 8534699
Drug: Once-daily dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dose gentamicin
Study: 8534699
Drug: Multiple-dose gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose gentamicin
Study: 6286517
Drug: Dexamethasone administration
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone administration for 3 days prior to the test
Study: 6286517
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 25 U of corticotropin 30 min pre-exercise
Study: 15250431
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education and home physical therapy
Study: 15250431
Drug: Education and
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education and physical therapy
Study: 7865687
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UH) 50 IU/kg i.v. with protamine sulphate (PS) 1 mg/100 IU of heparin
Study: 7865687
Drug: Tinzaparin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin 50 anti-factor Xa IU/kg i.v. with PS 1 mg/100 IU of heparin
Study: 7865687
Drug: Tinzaparin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin 75 anti-factor Xa IU/kg s.c. with PS 1 mg/100 IU of heparin
Study: 7865687
Drug: Tinzaparin 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin 175 anti-factor Xa IU/kg s.c. with PS 1 mg/100 IU of heparin
Study: 7865687
Drug: Saline s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline s.c. with PS 0.5 mg/kg
Study: 31238591
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care group (n = 33)
Study: 28844990
Drug: Pharmaco-invasive strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaco-invasive strategy with half-dose alteplase